Author(s): Yamashina S, Konno A, Wheeler MD, Rusyn I, Rusyn EV,
Abstract Share this page
Abstract Glycine inhibited growth of B16 melanoma tumors in vivo most likely because of the inhibition of angiogenesis. Here, the hypothesis that the anticancer effect of glycine in vivo is due to expression of a glycine-gated Cl- channel in endothelial cells was tested. First, the effects of glycine on vascular endothelial growth factor-induced increases in intracellular Ca2+ concentration in a bovine endothelial (CPA) cell line were studied. Vascular endothelial growth factor (1 ng/ml) increased intracellular Ca2+ concentration, with peak values reaching 141 +/- 11 nM. Glycine blunted this increase dose dependently. Furthermore, the inhibitory effects of glycine were prevented by 1 microM strychnine, a glycine receptor antagonist, or when cells were incubated in Cl(-)-free buffer. Moreover, glycine increased influx of 36Cl into CPA cells approximately 10-fold; this reaction was also strychnine sensitive. Furthermore, mRNA similar to the beta-subunit of the glycine-gated Cl- channel from spinal cord was identified in endothelial cells by reverse transcription-polymerase chain reaction. In addition, Western analysis using antibody for the glycine receptor demonstrated expression of the beta-subunit of the glycine receptor. Importantly, glycine diminished serum-stimulated proliferation and migration of endothelial cells. Collectively, these data indicate that the inhibitory effect of glycine on growth and migration of endothelial cells is due to activation of a glycine-gated Cl- channel. This hyperpolarizes the cell membrane and blocks influx of Ca2+, thereby minimizing growth factor-mediated signaling.
This article was published in Nutr Cancer
and referenced in Journal of Glycomics & Lipidomics